November 07, 2023
1 min watch
Save
VIDEO: Belzutifan promising in renal cell carcinoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MADRID — In this video, Sumanta (Monty) Pal, MD, FASCO, shared his excitement about belzutifan data, a “big development” of ESMO Congress, in the renal cell carcinoma space.
“It appears that belzutifan is going to emerge as a practical choice for us in the third- and fourth-line setting,” Pal, co-director of City of Hope’s Kidney Cancer Program, HemOnc Today Editorial Board Member and member of the Kidney Cancer Association's Medical Steering Committee, told Healio.
He believes that there will be “a tremendous place” for belzutifan (Welireg, Merck) among certain patients.
References:
- Agarwal N, et al. Abstract 1881O. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
- Albiges L, et al. Abstract LBA88. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
- Choueiri T, et al. Abstract LBA87. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Pal reports travel accommodations/expenses for CRISPR Therapeutics and Ipsen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.